<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600364</url>
  </required_header>
  <id_info>
    <org_study_id>DP64/BO1507</org_study_id>
    <nct_id>NCT02600364</nct_id>
  </id_info>
  <brief_title>Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device</brief_title>
  <official_title>Prospective, Multicenter, Single Arm Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenox GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phenox GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and effectiveness of the p64 Flow Modulation
      Device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Diversion-p64. Device: p64 Flow Modulation Device. Study design: Prospective,
      multicenter, single arm Post Market Clinical Follow-Up Study.

      Purpose: To assess safety and effectiveness of p64. Study duration: 48 months. Sample Size:
      400 patients. Number of sites: &gt; 20. Follow-up intervals: Two independent follow-ups (after
      3-6 and 7-12 months) according to site specific standard.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the rate of complete occlusion</measure>
    <time_frame>immediately after treatment, an expected average of 1 hour; to 12 months</time_frame>
    <description>Rate of complete aneurysm occlusion is assessed immediately after treatment (an expected average of 1 hour) and at both follow-up visits (3-6 months and 7-12 months). The change is assesed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of frequency of major stroke (ischemic or hemorrhagic) or neurological death related to the treatment of the target aneurysm</measure>
    <time_frame>immediately after treatment, an expected average of 1 hour; to 12 months</time_frame>
    <description>Frequency of major stroke (ischemic or hemorrhagic) or neurological death is assessed immediately after treatment (an expected average of 1 hour) and at both follow-up visits (3-6 months and 7-12 months). The change is assesed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-procedural technical complications</measure>
    <time_frame>during treatment, an expected average of 1 hour</time_frame>
    <description>p64 placed in the desired location Correct opening of p64 (markers fully deployed) at the end of the procedure Ability to detach p64 at the end of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Angiographic results</measure>
    <time_frame>immediately after treatment, an expected average of 1 hour; to 12 months</time_frame>
    <description>Change in both Rate of re-growth (related rate of re-treatment) and Rate of recanalization (related rate of re-treatment) are assessed immediately after treatment (an expected average of 1 hour) and at both follow-up visits (3-6 months and 7-12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-procedural vascular complications</measure>
    <time_frame>during treatment, an expected average of 1 hour</time_frame>
    <description>Vessel perforation (e.g. with distal wire tip of p64, microcatheter) Target aneurysm perforation (e.g. with distal wire tip of p64, microcatheter) Thromboembolism Dissection of any access vessel Side branch occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedural Complications</measure>
    <time_frame>3-6 and 7-12 months</time_frame>
    <description>Parenchymal hemorrhage detected during the follow-up period Subarachnoid hemorrhage detected during the follow-up period Ischemic stroke detected on follow-up imaging Rupture of the target aneurysm detected during the follow-up period Rate of in-stent-stenosis detected during the follow-up period</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for this non-interventional study are patients with ruptured or
        unruptured aneurysms and segmental diseases in the anterior circulation. Patients can be
        included in the study if they meet all of the inclusion and none of the exclusion criteria
        and have provided written informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age ≥ 18

          2. Patient harbours either one saccular or one dissecting or one blisterlike or one
             fusiform intracerebral aneurysm or one intracerebral segmental disease, in the
             anterior circulation for which the indication for p64 treatment is given

          3. Patient or legal representative provides written informed consent verifying that
             he/she consents to the use of his/her data (according to the data protection laws)

        Exclusion Criteria

          1. Aneurysms of the posterior circulation

          2. Imaging evidence of bifurcation aneurysms

          3. Imaging evidence of dissections

          4. Imaging evidence of fistulae

          5. Imaging evidence of arteriovenous malformations

          6. Patient is harbouring another aneurysm that has to be treated within six months after
             first procedure

          7. Known allergy to study medication, e.g. ASA, Clopidogrel, Heparin or contrast media

          8. Confirmation of positive pregnancy test according to site specific standard of care
             (e.g. test, verbal communication)

          9. Current involvement in another study or trial

         10. Parent vessel treated with other Flow Diverters than p64 during intervention and
             re-treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Bonafé, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Gui de Chauliac (CHU de Montpellier), Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica La Sagrada Familia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1642</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Ivan Rilski Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre Cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac (CHU Montpellier)</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau (CHRU de Tours)</name>
      <address>
        <city>Tours cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Recklinghausen</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria Carlo Alberto Pizzardi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalny Szpital Specjalistyczny</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny we Wroclawiu</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Memorial Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>010718</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NSI Burdenko, Moscow</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Almazov North-West Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS TRUST</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://phenox.net/</url>
    <description>www.phenox.net</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aneurysm</keyword>
  <keyword>intracerebral</keyword>
  <keyword>stroke</keyword>
  <keyword>p64</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

